Persephone Biosciences

Persephone Biosciences, founded in the summer of 2017 by Dr. Stephanie Culler and Dr. Steve Van Dien, is a synthetic biology company focused on developing microbiome-based medicines for patient and infant health. The founders, who are pioneers in synthetic and metabolic engineering, established the company to leverage their expertise in engineering microbes to address significant health challenges. Dr. Culler, the CEO, holds a Ph.D. in Chemical Engineering from Caltech and previously worked as a senior scientist at Genomatica, a company that engineers microbes for sustainable chemicals. This experience in programming microbes for industrial applications inspired her to apply similar principles to human health, a motivation reinforced by personal losses to cancer. Dr. Van Dien, the CTO, has an extensive background in metabolic engineering and industrial microbiology, with a Ph.D. in Chemical Engineering from UC Berkeley and a 13-year tenure at Genomatica, where he led a team that successfully developed a commercial process for producing BDO from sugars.

The company's business is structured into two main divisions: Persephone Therapeutics and Persephone Consumer Health. Persephone Therapeutics focuses on oncology, developing microbial therapies to improve the efficacy of existing cancer treatments. A core component of this division is the ARGONAUT study, a large-scale clinical trial in the U.S. designed to identify biomarkers for cancer treatment by mapping the gut-immune axis. The company utilizes artificial intelligence and multi-omics analysis on patient samples to design microbial drugs that can prevent and fight cancer. Persephone has established collaborations with major pharmaceutical and health companies, including Janssen Biotech (a Johnson & Johnson company) and Kroger Health, to advance its research in this area.

Persephone Consumer Health is dedicated to infant and adult wellness. A key initiative is the My Baby Biome™ clinical study, one of the largest U.S. studies on infant gut health, which aims to address infant gut dysbiosis. This research has led to the development of synbiotic products for infants and toddlers, combining novel probiotic strains of Bifidobacteria with matching prebiotics (human milk oligosaccharides) and Vitamin D. These products, expected to launch by the end of 2025, are designed to restore beneficial microbes that are now often missing in infants, supporting immunity and healthy development. The company's revenue model appears to be based on the future commercialization of these therapeutic and consumer health products, supported by significant seed funding, including a $15 million round in 2022, from investors like Y Combinator, First Bight Ventures, and Propel Bio Partners.

Keywords: microbiome therapeutics, synthetic biology, gut health, oncology, infant health, immuno-oncology, live biotherapeutics, microbial medicine, cancer treatment, precision medicine, synbiotics, probiotics, metabolic engineering, clinical trials, gut-immune axis, infant gut dysbiosis, biomarker discovery, ARGONAUT study, My Baby Biome, microbial engineering